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Objectives: This studyaimed to define themolecular basis of co-trimoxazole resistance inMalawianpneumococci
under the dual selective pressure of widespread co-trimoxazole and sulfadoxine/pyrimethamine use.
Methods:Wemeasured the trimethoprim and sulfamethoxazole MICs and analysed folA and folP nucleotide and
translated amino acid sequences for 143 pneumococci isolated from carriage and invasive disease in Malawi
(2002–08).
Results: Pneumococci were highly resistant to both trimethoprim and sulfamethoxazole (96%, 137/143). Sulfa-
methoxazole-resistant isolates showeda3or6 bp insertion in thesulphonamide-binding siteof folP. The trimetho-
prim-resistant isolates fell into three genotypic groups based on dihydrofolate reductase (encoded by folA)
mutations: Ile-100-Leu (10%), the Ile-100-Leu substitution together with a residue 92 substitution (56%) and
those with a novel uncharacterized resistance genotype (34%). The nucleotide sequence divergence and dN/dS
of folA and folP remained stable from 2004 onwards.
Conclusions: S. pneumoniae exhibit almost universal co-trimoxazole resistance in vitro and in silico thatwe believe
is driven by extensive co-trimoxazole and sulfadoxine/pyrimethamine use. More than one-third of pneumococci
employa novelmechanism of co-trimoxazole resistance. Resistance has now reached a point of stabilizing evolu-
tion. The use of co-trimoxazole to prevent pneumococcal infection in HIV/AIDS patients in sub-Saharan Africa
should be re-evaluated.
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Introduction
Insub-SaharanAfrica,Streptococcuspneumoniae is oneof themost
common causes ofmeningitis and pneumonia. The combination of
trimethoprim and sulfamethoxazole (co-trimoxazole) is recom-
mended by WHO for prophylaxis in HIV/AIDS patients to prevent
opportunistic bacterial infections and Pneumocystis jirovecii.1
Co-trimoxazole preventative therapy (CPT) became national policy
in Malawi in 2005 and is now administered across all government-
funded hospitals. In 2006, 34942 Malawians were registered to
receive CPT; by the end of 2010 this figure had increased to
189520.2 Between 1993 and 2007, sulfadoxine/pyrimethamine
was the recommended first-line treatment for uncomplicated
malaria in Malawi and was used to prevent malaria in pregnancy.3
Prior to the introduction of CPT, co-trimoxazole resistance in
S. pneumoniae in Malawi was already high at 74% and since 2005
resistance has been consistently above 90%.4
Co-trimoxazole and sulfadoxine/pyrimethamine both target
dihydrofolate reductase (DHFR) and dihydropteroate synthase
(DHPS), allowing cross-resistance mechanisms to these two
antimicrobials.5 DHFR and DHPS form part of the folic acid biosyn-
thetic pathway. Co-trimoxazole and sulfadoxine/pyrimethamine
act as false substrate inhibitors, preventing folic acid biosynthesis
and bacterial cell growth. Resistance to co-trimoxazole and sulfa-
doxine/pyrimethamine is conferred by acquisition of mutations
in folA and folP, the genes encoding DHFR and DHPS, respectively.
# The Author 2013. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. This is an Open Access
article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits
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Althoughmultiplemutations have been reported in trimethoprim-
resistant pneumococci, the single substitution Ile-100-Leu inDHFR
is sufficient to confer resistance.6,7 In sulfamethoxazole-
resistant isolates, folP is characterized by a 3 or 6 bp insertion,
resulting in the insertion of one or two amino acids in the DHPS
sulphonamide-binding site.8–10
We analysed the folA and folP sequences of 143 pneumococci
isolated from carriage and invasive disease following the introduc-
tionofCPT inMalawi, todefinethemolecularbasisofco-trimoxazole
resistance under the dual selective pressure of widespread co-
trimoxazole and sulfadoxine/pyrimethamine use.
Methods
Ethics
Weperformed a detailed characterization of bacterial isolates from clinical
specimens taken from patients for clinical reasons. The isolates used in the
study were anonymized. These data are publishedwith the approval of the
University of Malawi College of Medicine Research & Ethics Committee and
conform to institutional guidelines.
Study isolates
TheMalawi-Liverpool-WellcomeTrust Clinical Research Programme (MLW),
based at Queen Elizabeth Central Hospital (QECH) in Blantyre, Malawi, has
archived over 5000 pneumococcal isolates since 1996. A convenience
sample of 143 pneumococci, collected between 2002 and 2008, was
selected from the archive as part of a study into the genetic diversity of
S. pneumoniae prior to the roll-out of 13-valent pneumococcal conjugate
vaccine in Malawi.11 The selected isolates encompassed 35 serotypes
and 68 multilocus sequence typing (MLST) sequence types (STs);12 65 iso-
lates belonged to one of 48MLST STs that had not previously been reported
to theMLSTdatabase and are here referred to as STunknown, followed bya
number. One hundred and thirty-one pneumococci were from invasive
disease (92%of the total) and12were fromnasopharyngeal carriage (8%).
Culture and extraction methodologies
Co-trimoxazole susceptibility was assessed using the BSAC disc diffusion
method.13 Sulfamethoxazole and trimethoprim MICs were determined by
the Etest (AB Biodisk, Solna, Sweden) according to the manufacturer’s
instructions. S. pneumoniae ATCC 49619 was used as a quality control
strain and gave values within an acceptable reported range.
S. pneumoniae isolates that had been stored inMicrobank bacterial pre-
servers (Prolab Diagnostics, Ontario, Canada) were streaked onto blood
agar plates and incubated at 378C for 18 h. Single isolated colonies were
suspended in Todd–Hewitt Broth (Oxoid, Basingstoke, UK) and incubated
at 378C for 18 h. The cells were sedimented by centrifugation and resus-
pended in 480 mL of 50 mM EDTA and 120 mL of lysozyme and incubated
at 378C for 1 h. Genomic DNA was prepared from the lysate using a
Promega Wizard Genomic DNA purification kit (Promega, Madison, USA).
Multiplex DNA sequencing was performed with an Illumina Genome Ana-
lyzer GAII (Illumina, CA,USA), as describedelsewhere.14 All of the sequence
reads generated are deposited in the short read archive (National Centre
for Biotechnology Information) under the accession numbers ERP000185
and ERP000152. Reads were assembled using Velvet v1.0.03,15 and con-
tiguated against a complete reference sequence (accession number
FM211187) using ABACUS.16 Serotype and MLST STs were determined as
previously described.17 The folA and folP genes were identified by BLAST
searching folA_R6 (Gene ID 4442919) and folP_R6 (Gene ID 4443057)
from the fully susceptible laboratory reference strain S. pneumoniae R6 (tri-
methoprim MIC 2 mg/L; sulfamethoxazole MIC 16 mg/L). Significant hits
Table 1. Amino acid variation of DHPS from sulfamethoxazole-resistant
pneumococci in relation to the co-trimoxazole-susceptible laboratory
reference S. pneumoniae R6
folP insertion DHPS mutationa
Number of
isolates (%)
Previously reported
in S. pneumoniae
Wild-type — 5 (3) 30
6 bp STRPRPGSSYVEIE 88 (65) 8,9,30
3 bp STRPGR_SSYVEIE 21 (15) 8
6 bp STRPSSSSSYVEIE 15 (10) 30
6 bp STRPGSYSSYVEIE 2 (1) 10
6 bp STRPGTGSSYVEIE 6 (4) —
6 bp STRPGSSYVEVEIE 2 (1) —
6 bp STRPGSSYVEIEIE 4 (3) 8,10,31
Amino acid insertions are in bold italics.
aRepresentsaminoacidresidues56–67 in theaminoacidsequenceofDHPS
from S. pneumoniae R6.
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Figure 1. Diversity of folP from Malawian pneumococci, 2003–08.
(a) Annual sequence divergence of folP from pneumococci in relation to
the co-trimoxazole-susceptible laboratory reference strain S. pneumoniae
R6. (b) Graph showing the annual dN/dS of folP from pneumococci in
relation to the co-trimoxazole-susceptible laboratory reference strain
S. pneumoniae R6.
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were viewed, edited and annotated in Artemis V11.22.18 Nucleotide
sequences of folA and folP were aligned separately in Seaview V4.119
using Muscle V3.7.20 The nucleotide sequences were translated into
amino acid sequences and a second alignment was performed.
The ratio of non-synonymous to synonymous single-nucleotide poly-
morphisms (dN/dS SNPs) in folA and folP for each isolate was computed
using the Nei–Gojobori method.21
Phylogeny construction
Phylogenetic trees were constructed using RAxML v.7.0.422 using the nu-
cleotidealignments. A generalized time-reversiblemodelwith gammacor-
rection for among-site variationwas usedwith 10 iterations using different
starting trees. To assess support for relationships in the tree, 100 random
bootstrap replicates were performed. folA_R6 or folP_R6 was included as
an outgroup.
Results
In vitro resistance
Co-trimoxazole resistance amongst the study isolates was 96%
(137/143). The MICs of sulfamethoxazole and trimethoprim for all
resistant isolates were .1024 and .32 mg/L, respectively. This is
veryhigh-level resistance tobothantimicrobials basedonBSACdefi-
nitions.13 Six isolates were susceptible to co-trimoxazole. Five co-
trimoxazole-susceptible isolates (53,88, 96, 127and147)were sus-
ceptible to both trimethoprim and sulfamethoxazole (MICs 12 and
96 mg/L, respectively). The remaining co-trimoxazole-susceptible
isolate, isolate 137, was susceptible to trimethoprim but resistant
to sulfamethoxazole (MICs 6 and.1024 mg/L, respectively).
Molecular markers of sulfamethoxazole resistance
All sulfamethoxazole-resistant isolates displayed an insertion of 3
or 6 bp in folP, resulting in the insertion of one or two amino acids
between Arg-58 and Ile-66 of DHPS, an area hypothesized to
form the sulphonamide-binding site.7 The five sulphonamide-
susceptible isolates did not display amino acid insertions in this
area (Table 1). No additional mutations were detected that were
unique to the sulphonamide-resistant isolates.
Themean nucleotide sequence divergence of folP, in relation to
folP_R6, was relatively stable over the isolate collection period,
from 5.66% in 2004 to 5.72% in 2008 (P¼0.6) (Figure 1a). The
mean dN/dS ratio of folP also remained stable over the same
period, from 0.10 in 2004 to 0.12 in 2008 (P¼0.09) (Figure 1b).
Amaximumlikelihood treeconstructedusing thenucleotidese-
quence of folP from the 143 study isolates is presented in Figure 2.
With the exception of isolate 127, all of the sulfamethoxazole-
susceptible isolates formed a single clade separate from the
trimethoprim-susceptible folA_R6.All of the serotype1 isolates, re-
gardlessof their ST, sharedan identical folPsequenceandclustered
in a distinct clade. Of the 20 STs representedmore than once in the
study population, 16 shared identical folP sequences within all
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Figure 2. Maximum likelihood phylogenetic tree based on the folP SNPs
from 143 Malawian pneumococci, annotated with serotype and ST. STs
represented more than twice in the study population that did not cluster
on the same clade are highlighted by a symbol: STunknown22, star;
ST347, triangle; Stu48, square; STunknown17, circle. Bootstrap values are
shown on each branch. The scale bar represents the number of SNPs.
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isolates belonging to that ST; 16 separate clades were formed in
the phylogeny, each consisting of isolates with only a single ST.
The remaining four STs did not share identical folP sequences,
and the isolates belonging to each ST sat on a distinct lineage
within the phylogeny. Three serotype 7F, STunknown48 isolates
were represented in the study collection (isolates 74, 75 and 76).
Isolates75and76shared identical folP sequencesandgrouped to-
gether in the same clade; however, isolate 74 sat in a distinct clade
with ST16, ST63, ST6872 and STunknown32. The folP sequence of
isolate 74 was 6.8% divergent from that of isolates 75 and 76.
Isolate 74 had an folP sequence identical to that of the four
other STs belonging to the same clade.
Two of three serotype 12B STunknown17 isolates, 50 and 51,
grouped in the same clade; however, a third, isolate 65, sat in a
cladewith serotype12BST989. Isolates 51and50hadan identical
folP sequence, but the sequence diverged from that of the folP of
isolate 65 by 7.2%. The two 18B, STunknown22 isolates (isolates
94 and 95) represented in the study population did not sit together
on the tree. Therewas5.6%sequencedivergence between the folP
fromthe two isolates. The twoserotype19F, ST347 isolatesalsosat
apart in distinct clades (7.3% sequence divergence). The nucleo-
tide sequence of folP from isolate 62 was unique within the study
population, whilst isolate 63 had an identical folP sequence to
isolate 12B, STunknown17, which sat on the same clade as
isolate 63.
Molecular markers of trimethoprim resistance
Nucleotide sequences of folA from all isolates were determined
and compared with folA_R6. There was an annual increase in se-
quence divergence from 2.82% in 2004 to 4.75% in 2008;
however, this increase was not significant (P¼0.125) (Figure 3a).
The dN/dS ratio of folA could not be calculated for 12 isolates as
these isolates only displayed non-synonymous SNPs within the
gene. The dN/dS ratio was calculated for the remaining 131 iso-
lates. There was an annual decrease in the dN/dS ratio of folA,
from 0.3 in 2004 to 0.2 in 2008; this decrease was not significant
(P¼0.72) (Figure 3b).
Amino acid sequences of DHFR were predicted and analysed.
Amino acid substitutions at two residues were dominant within
Table 2. Amino acid variation at residues 92 and 100 of DHFR
from trimethoprim-resistant pneumococci in relation to the
co-trimoxazole-susceptible laboratory reference S. pneumoniae R6
DHFR mutation Number of isolates (%)
Asp-92-Arg, Ile-100-Leu 54 (41)
Asp-92-Arg 41 (30)
Asp-92-Thr, Ile-100-Leu 19 (14)
Asp-92-Gly, Ile-100-Leu 10 (8)
Asp-92-Val, Ile-100-Leu 8 (6)
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Figure 3. Diversity of folA from Malawian pneumococci 2003–08. (a)
Annual sequence divergence of folA from Malawian pneumococci in
relation to the co-trimoxazole-susceptible laboratory reference strain S.
pneumoniae R6. (b) Graph showing the annual dN/dS of folA from
Malawian pneumococci in relation to the co-trimoxazole-susceptible
laboratory reference strain S. pneumoniae R6.
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Figure 4. Annual distribution of three resistance genotypes amongst 137
trimethoprim-resistant Malawian pneumococci.
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the study population, I100L and substitutions at residue 92
(Asp-92 to Ala, Gly, Val or Thr) (Table 2). The trimethoprim-
resistant isolates could be assigned to one of three genotypic
groups: those containing Ile-100-Leu (10%); those containing
Ile-100-Leu in combination with a substitution at residue 92
(56%); and those containing a substitution at residue 92 with
the wild-type amino acid at residue position 100 (34%). In this
third group, the amino acid substitution at residue 92 was
always Asp-92-Ala.
Other amino acid substitutions that were unique to the tri-
methoprim binding site of the resistant isolates were Pro-70-Leu,
Ala-78-Thr, Glu-94-Asp and Leu-135-Phe. Six trimethoprim-
resistant isolates contained Asp-92-Ala, with no other amino
acid substitutions in the trimethoprim-binding site.
The distribution of three genotypic groups amongst the
trimethoprim-resistant pneumococci on an annual basis is
shown in Figure 4. A trend analysis comparing all of the study
years showed a significant increase in the number of pneumococci
possessing thedualgenotypeover thestudyperiod (P¼0.045). The
change in the number of pneumococci possessing the Ile-100-Leu
phenotype was not significant (P¼0.67). There was a decrease in
the number of pneumococci with the Asp-92 mutations;
however, this was not significant (P¼0.06).
A maximum likelihood tree constructed using the 138 variable
sites in folA from the 143 study isolates is presented in Figure 5.
The trimethoprim-susceptible isolates did not cluster together on
the tree, sitting on four distinct clades. The STwas a poor indicator
of how isolates would cluster on the tree. Only three STs (STun-
known48, ST705 and STunknown13) shared identical folA
sequences and clustered together on the tree. The remaining 17
STs did not cluster together and were dispersed across multiple
folP lineages within the phylogeny. Isolates belonging to ST289
were represented in four distinct folP lineages.
Discussion
We propose that extensive use of both co-trimoxazole and sulfa-
doxine/pyrimethamine in Malawi has been a major driving force
behind the evolution and maintenance of co-trimoxazole resist-
ance in Malawian pneumococci. Resistance amongst pneumo-
cocci to co-trimoxazole was already high (74%) before the
introduction of CPT in 2002. A previous study of Malawian children
aged,5 years found that sulfadoxine/pyrimethamine treatment
led to a significant increase in the proportion of children colonized
with co-trimoxazole-non-susceptible pneumococci.23 After the
introduction of CPT, resistance rose to 92%. It has previously
been reported that there is a significant correlation between re-
gional consumption of co-trimoxazole and resistance in pneumo-
cocci in the following year24 and we believe the increased
resistance is a result of extensive use of co-trimoxazole locally.
All of the sulfamethoxazole-resistant isolates possessed a 3 or
6 bp insertion in the nucleotide sequence encoding amino acids
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58–67 of DHPS. This has previously been described as a hot spot
for mutations in sulfamethoxazole-resistant pneumococci.3,9,10
The most common insertions led to the duplication of Arg-58
and Pro-59 and the insertion of an arginine residue between
Gly-60 and Ser-61. These mutations have been previously shown
to confirm resistance.8 Two mutations, the Val64Glu65 and
Gly60Thr61 repetitions described here, are novel. The role of these
mutations in sulfamethoxazole resistance has yet to be estab-
lished; however, their location in the sulphonamide-binding site
amongst resistant isolates strongly suggests that thesemutations
reduce the affinity of sulfamethoxazole for DHPS.
The phenotypic and genotypic characterization presented here
shows that Malawian pneumococci are almost universally resistant
to sulfamethoxazole. Previous studies have shown that insertions in
the sulphonamide-binding site leading to a drastic reduction in the
binding affinity to sulfamethoxazole have minimal impact on the
binding affinity of DHPS to its natural substrate.10 This suggests
that, despite removal of sulfadoxine/pyrimethamine selective pres-
sure on folP, sulfamethoxazole-resistant pneumococciwill continue
to dominate within the population as the resistance imposes
minimal fitness cost.
Clonal dissemination of specific STs appears to be responsible
for the dominance of sulphonamide resistance in Malawi. Phylo-
genetic analysis demonstrated that ST was a strong indicator of
isolate grouping. The 6.8% sequence divergence between folP
from isolate 74 and folP from 75 and 76, all of which were STun-
known48, is unlikely to have resulted from spontaneous mutation
alone. The folP sequence encoded by isolate 74 was identical to
that of isolates from four different serotypes, all of which were in
the same clade. The presence of multiple STs in the same folP
lineage is strongly suggestive of recombination. The folP sequence
of ST989 of isolate 70 was identical to that of isolate 65. The high
level of sequence divergence between folP from isolates belonging
toST989, STunknown22andST347 (7.2%,5.6%and7.3%, respect-
ively) suggests that folP encoding DHPS with reduced affinity for
sulfamethoxazole has spread via recombination.
Our data show that, of the Malawian pneumococci that were
trimethoprim resistant (MIC .32 mg/L), one-third possessed a
previously unreported resistance genotype, a mutation at residue
92 without Ile-100-Leu in DHFR, and suggest a potentially novel
resistance mechanism. Previous studies report I100L as critical
for the generation of trimethoprim resistance in pneumococci,
while an additionalmutation at residue 92 causes a further signifi-
cant increase in MIC.6 The substitution at residue 92 without the
Ile-100-Leu mutation has been considered insufficient to confer
trimethoprim resistance.25 The majority of isolates (56%) pos-
sessed Ile-100-Leu with an additional mutation at residue 92,
and 10% contained Ile-100-Leu alone. Amongst those exhibiting
the novel genotype therewere no further amino acid substitutions
in the trimethoprim-binding site. Amino acid substitutions outside
the trimethoprim-binding site in DHFR were also found in the five
trimethoprim-susceptible isolates, suggesting that they do not
play a role in resistance. Trimethoprim-resistant pneumococci
that do not possess the Ile-100-Leu substitution in DHFR have
not been described previously. Further investigation is required to
determine whether this novel pattern is unique to Malawi or has
simply not yet been described in other geographical locations
due to the small numbers of folA genes sequenced to date.
Our data suggest that extensive co-trimoxazole use has biased
the selection of pneumococci resistant to trimethoprim. The
number of isolates with a mutation at position 92 but no
Ile-100-Leu mutation and those encoding the Ile-100-Leu with
the wild-type residue at position 92 decreased between 2004
and 2008. In parallel there was a significant increase in those pos-
sessing Ile-100-Leu with an additional mutation at residue 92.
Over the same timeperiodCPT increased substantially in thepopu-
lation. The additional mutation at position 92 has been shown to
significantly reduce theaffinityofDHFR for trimethoprim in relation
to the Ile-100-Leu alone.6
Of the 20 STs represented more than once in the study popula-
tion, only three sharedan identical folA sequence and clustered to-
gether in the phylogeny. ST did not predict how the remaining 17
STswould cluster in the phylogeny, suggesting that recombination
plays a major role in the spread of trimethoprim resistance. It is
unclear why folA and folP are being disseminated by different
mechanisms.
There was an increase in the sequence divergence of folA
amongst the isolates, matched by a decrease in dN/dS ratio from
2004 to 2008. Neither change was significant, suggesting the se-
quence divergence of folA from that of folA_R6 has remained con-
stant. During the same timeperiod the sequencedivergenceof folP
from folP_R6 remained relatively stable, withminor drift. The years
2002 and 2003 were excluded from the analysis because the
sample contained fewer than three isolates from each of these
years. The dN/dS ratio also remained stable from 2004 to 2008
despite extensive co-trimoxazole use. Irrespective of isolation
date, all resistant isolates displayed very high-level resistance
to both trimethoprim and sulfamethoxazole. The sequence
data therefore demonstrate that the evolution of both folA and
folP is stable in theMalawian pneumococcal population.We pos-
tulate that the strong selective pressure of extensive co-
trimoxazole and sulfadoxine/pyrimethamine use over more
than a decade means mutations additional to folA and folP will
provide no additional fitness advantage, as the bacteria are
now almost universally resistant.
In conclusion, theemploymentof bothan in vitroandan in silico
analytical approachhasenabledus todescribe indetail thegenetic
basis of co-trimoxazole resistance in S. pneumoniae in Malawi. By
creating robust phylogenies we have established that clonal dis-
semination and recombination are contributing to the spread of
co-trimoxazole resistance. Previously reported conventional
testing for co-trimoxazole resistance in countries with high HIV
seroprevalence has led to considerable debate as to why, with
such high levels of pneumococcal resistance, clinical efficacy is
maintained.26,27 However, in the context of stabilizing evolution
in silico, we suggest that the protective effects of co-trimoxazole
in this vulnerable populationmay have changed since the relevant
trials were conducted.10 years ago.28,29Our findings are likely to
be generalizable to other countries where co-trimoxazole and
sulfadoxine/pyrimethamine have been widely used. We therefore
suggest that the efficacy of co-trimoxazole prophylaxis against
pneumococcal infection in HIV/AIDS in sub-Saharan Africa
should be re-evaluated.
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